AGM, page-12

I am really disappointed with current management for not informing the market on the DARRT-2 trial as you can see below from the DARRT-1 Trial we were informed of the trial progress much earlier than the current trial. We received the results at 12 weeks, 24 weeks of the trial. The current trial has been going for over 52 weeks surely there would be some results.


The results of DARRT-1 were very encouraging.

Disease progression stopped, or the clinical status improved in a majority of patients at 12 week and 24 week follow upA majority of patients achieved a clinically meaningful pain response at 12 weeks and at 24 weeks.

Notably some patients were pain-free at 24 weeks .PSA levels dropped by over 50% in a number of patients at 12 weeks this effect was found to persist for most of those individuals at 24 weeks. PSA (prostate specific antigen) in cancer therapy is an indicator of disease activity.

An abscopal effect was noted in 4 patients, indicative of an immuno-oncological effect. In these patients, both the irradiated tumour and tumours outside of the radiation field shrank.